Tumour mutational burden: an overview for pathologists
Loading...
Citations
Scopus:
Altmetric:
Altmetric::
Download
Associated Records
Authors
File Licence
Editors
Date
2022-04-01
Source Title
Pathology
Journal Title
Journal ISSN
Volume Title
Publisher
ELSEVIER
Melbourne Authors
Affiliation
Sir Peter MacCallum Department of Oncology
Document Type
Journal Article
Subject Code
Citation
Doig, K. D., Fellowes, A., Scott, P. & Fox, S. B. (2022). Tumour mutational burden: an overview for pathologists. Pathology, 54 (3), pp.249-253. https://doi.org/10.1016/j.pathol.2021.11.008.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Cancer immunotherapy holds great promise and has shown durable responses in many patients; however, these responses are not uniform in all patients or all tumour streams. There is an ongoing clinical need for objective diagnostic biomarkers to identify patients that will respond to immunotherapies. Tumour mutational burden (TMB) is a diagnostic biomarker that can stratify cancer patients for response to immune checkpoint inhibitor therapies. It is commonly defined as the average number of somatic mutations per megabase in a tumour exome. Here we describe the TMB biomarker, how it is determined, its underlying molecular basis, the relationship to neoantigens and the issues around its clinical use. This overview is directed toward practising pathologists wishing to be informed of this predictive biomarker.